Charles River partners with Milner Therapeutics Institute and Consortium
The Milner Therapeutics Institute works to accelerate academic research and as party of this endeavor, the institute’s outreach program, the Milner Therapeutics Consortium, connects academics with the industry.
Emily Hickey, DVM, Ph.D., Corporate Senior VP, Global Discovery Services at Charles River, said the partnership with Milner Therapeutics will further enable “collaboration between academics and pharmaceutical companies as they partner to investigate the therapeutic potential of their research.”
As part of the partnership, academic institutions in the consortium will gain access to Charles River’s early discovery and drug development resources and services.
According to the company, Charles River is the early-stage contract research organization (CRO) to partner with the Milner Therapeutics Institute and Consortium.
The Consortium currently includes, Astex, AstraZeneca, GlaxoSmithKline, and Shionogi, as well as the University of Cambridge, Babraham Institute, and Sanger Institute.
In June, the Consortium held a Symposium to bring academia and industry together as it looks for new partners. According to the Consortium, in the two month period ending in June 13, 2016, 18 new companies became affiliated with the Milner Therapeutics Institute, including Charles River Laboratories.
Prof Tony Kouzarides, founder and director of the Milner Therapeutics Institute and Consortium said, “We are building the foundations for a world-leading hub in Cambridge around the Milner Therapeutics Institute."
